New injection aims to help when antidepressants fail

NCT ID NCT06965569

Completed Disease control Sponsor: Alar Pharmaceuticals Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new drug called ALA-3000 in 37 adults with treatment-resistant depression — meaning their depression did not get better with standard antidepressants. Participants received either ALA-3000 injections or a placebo, along with a newly started oral antidepressant. The main goals were to check safety and how the body processes the drug, with a preliminary look at whether it might help symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ALA-3000 (injection) plus a standard antidepressant (escitalopram, sertraline, duloxetine, or venlafaxine XR)
What this could lead to: If successful, this could point toward a new treatment option for people with depression that hasn't responded to standard medications.
What could go wrong: This is a very early Phase 1 trial with only 37 people, focused mainly on safety. It is too small and preliminary to know if ALA-3000 actually works for depression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TREATMENT RESISTANT DEPRESSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Depressive Disorder, Treatment-Resistant

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TREATMENT RESISTANT DEPRESSION

Contacts and locations

Show contact details

Locations

Arch Clinical Trials

St Louis, Missouri, 63141, United States
Clinilabs Drug Development Corporation

Eatontown, New Jersey, 07724, United States
Neuro-Behavioral Clinical Research, Inc

North Canton, Ohio, 44720, United States
Pillar Clinical Research

Little Rock, Arkansas, 72204, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.